

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI784818

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JEFFREY D. WILSON	08/19/2022
	JOSE LUIS RIOS LIZARRAGA	08/25/2022
	SHIJIE ZHANG	01/27/2022
	ERIC SIMONE	02/15/2022
RECEIVING PARTY DATA		
Company Name:	AGIOS PHARMACEUTICALS, INC.	
Street Address:	88 SIDNEY STREET	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02139	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	PCT Number:	US1862197
CORRESPONDENCE DATA		
Fax Number:	6176079200	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6174496636	
Email:	eshea@mccarter.com	
Correspondent Name:	MCCARTER & ENGLISH LLP	
Address Line 1:	265 FRANKLIN STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02110	
ATTORNEY DOCKET NUMBER:	128748-00420	
NAME OF SUBMITTER:	Erin Shea	
SIGNATURE:	/Erin Shea/	
DATE SIGNED:	01/28/2025	
Total Attachments: 13		
source=AGI-PKR-16WO_ASSIGNMENT_ERIC SIMONE#page1.tiff		
source=AGI-PKR-16WO_ASSIGNMENT_ERIC SIMONE#page2.tiff		
source=AGI-PKR-16WO_ASSIGNMENT_ERIC SIMONE#page3.tiff		

source=AGI-PKR-16WO_ASSIGNMENT_JOSE LUIS RIOS LIZARRAGA#page1.tiff
source=AGI-PKR-16WO_ASSIGNMENT_JOSE LUIS RIOS LIZARRAGA#page2.tiff
source=AGI-PKR-16WO_ASSIGNMENT_JOSE LUIS RIOS LIZARRAGA#page3.tiff
source=AGI-PKR-16WO_ASSIGNMENT_SHIJIE ZHANG#page1.tiff
source=AGI-PKR-16WO_ASSIGNMENT_SHIJIE ZHANG#page2.tiff
source=AGI-PKR-16WO_ASSIGNMENT_SHIJIE ZHANG#page3.tiff
source=AGI-PKR-16_ASSIGNMENT_JEFFREY WILSON#page1.tiff
source=AGI-PKR-16_ASSIGNMENT_JEFFREY WILSON#page2.tiff
source=AGI-PKR-16_ASSIGNMENT_JEFFREY WILSON#page3.tiff
source=AGI-PKR-16_ASSIGNMENT_JEFFREY WILSON#page4.tiff

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, I, **Eric Simone of 174 Crane Neck Street, West Newbury, Massachusetts 01985**, hereinafter referred to as said Assignor, hereby:

Sell, assign and transfer to **Agios Pharmaceuticals, Inc.**, a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in the International Application for Patent filed with the United States Patent and Trademark Office as Receiving Office of the World Intellectual Property Organization in accordance with the Patent Cooperation Treaty (PCT) on

November 21, 2018

under International Application Serial No. **PCT/US2018/062197**

and

entitled **CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE**

and in and to said application and all continuing, divisional, continuation-in-part, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States and all foreign countries on said any and all inventions (including without limitation U.S. Provisional Application No. 62/589,822, filed November 22, 2017, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE, and U.S. Provisional Application No. 62/691,709, filed June 29, 2018, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE); and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said any and all inventions including the right to apply for patent rights in each foreign country and all rights to priority; and further including any right to sue for past infringement;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive Letters Patent for said any and all inventions in its own name; and when requested, without charge to but at the expense of said Assignee, I agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to me relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent

protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

In the event that the execution date, filing date and/or Application Number are not entered or are incorrect at the time Assignor executed this document, Assignor hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I, **Eric Simone**, have executed this document on the date indicated below.



Signature of Inventor

15 Feb 2022

Date


West Newbury, MA

Inventor's City, State of Residence

COMMONWEALTH OF MASSACHUSETTS:
COUNTY OF MIDDLESEX:

On this 15th day of February, 2022, before me, the undersigned notary public, personally appeared Eric Arthur Simone, proved to me through satisfactory evidence of identification, which were MA driver's license, to be the person whose name is signed on the preceding or attached document in my presence.

SEAL



Diane M. Riordan

Notary Public

My Commission Expires 1/6/2023

ACCEPTED AND AGREED TO BY ASSIGNEE: **Agios Pharmaceuticals, Inc.:**

Signature 

Date: 3/9/2022

Printed name: Rena Nardone

Title: Senior Director, IP

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, I, **Jose Luis Rios Lizarraga of 5 Portsmouth Street, Apt. 2, Cambridge, Massachusetts 02141**, hereinafter referred to as said Assignor, hereby:

Sell, assign and transfer to **Agios Pharmaceuticals, Inc.**, a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in the International Application for Patent filed with the United States Patent and Trademark Office as Receiving Office of the World Intellectual Property Organization in accordance with the Patent Cooperation Treaty (PCT) on

November 21, 2018

under International Application Serial No. PCT/US2018/062197

and

entitled **CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE**

and in and to said application and all continuing, divisional, continuation-in-part, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States and all foreign countries on said any and all inventions (including without limitation U.S. Provisional Application No. 62/589,822, filed November 22, 2017, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE, and U.S. Provisional Application No. 62/691,709, filed June 29, 2018, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE); and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said any and all inventions including the right to apply for patent rights in each foreign country and all rights to priority; and further including any right to sue for past infringement;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive Letters Patent for said any and all inventions in its own name; and when requested, without charge to but at the expense of said Assignee, I agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to me relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent

protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;


Request the Honorable Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

In the event that the execution date, filing date and/or Application Number are not entered or are incorrect at the time Assignor executed this document, Assignor hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I, **Jose Luis Rios Lizarraga**, have executed this document on the date indicated below.



Signature of Inventor

25 August 2022

Date


Cambridge, MA

Inventor's City, State of Residence

COMMONWEALTH OF MASSACHUSETTS:
COUNTY OF MIDDLESEX:

On this 25th day of August, 2022, before me, the undersigned notary public, personally appeared Jose Luis Rios Lizarraga, proved to me through satisfactory evidence of identification, which were U.S.A. passport, to be the person whose name is signed on the preceding or attached document in my presence.

SEAL




Diane M. Riordan

Notary Public

My Commission Expires 1/6/2023

ACCEPTED AND AGREED TO BY ASSIGNEE: **Agios Pharmaceuticals, Inc.:**

Signature 

Date: 9/6/2022

Printed name: Rana Narasim

Title: Senior Director, IP

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, I, **Shijie Zhang** of **27 Lojko Drive, Nashua, New Hampshire 03062**, hereinafter referred to as said Assignor, hereby:

Sell, assign and transfer to **Agios Pharmaceuticals, Inc.**, a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in the International Application for Patent filed with the United States Patent and Trademark Office as Receiving Office of the World Intellectual Property Organization in accordance with the Patent Cooperation Treaty (PCT) on

November 21, 2018

under International Application Serial No. **PCT/US2018/062197**

and

entitled **CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE**

and in and to said application and all continuing, divisional, continuation-in-part, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States and all foreign countries on said any and all inventions (including without limitation U.S. Provisional Application No. 62/589,822, filed November 22, 2017, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE, and U.S. Provisional Application No. 62/691,709, filed June 29, 2018, and entitled CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE); and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said any and all inventions including the right to apply for patent rights in each foreign country and all rights to priority; and further including any right to sue for past infringement;

Appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known;

Agree that said Assignee may apply for and receive Letters Patent for said any and all inventions in its own name; and when requested, without charge to but at the expense of said Assignee, I agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to me relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent

protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;


Request the Honorable Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

In the event that the execution date, filing date and/or Application Number are not entered or are incorrect at the time Assignor executed this document, Assignor hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I, **Shijie Zhang**, have executed this document on the date indicated below.



Signature of Inventor
Nashua, NH

Inventor's City, State of Residence

Jan. 27, 2022

Date

STATE OF NEW HAMPSHIRE:
COUNTY OF Rockingham:

On this 27 day of January, 2022, before me, the undersigned notary public, personally appeared Shijie Zhang, proved to me through satisfactory evidence of identification, which were NH Driver License, to be the person whose name is signed on the preceding or attached document in my presence.

SEAL



Notary Public
My Commission Expires 10/17/2023

Michael Wyand
Notary Public, State of New Hampshire
My Commission Expires Oct. 17, 2023

ACCEPTED AND AGREED TO BY ASSIGNEE: **Agios Pharmaceuticals, Inc.:**

Signature 

Date: 2/9/2022

Printed name: Rena Nardone

Title: Senior Director, IP

ASSIGNMENT

WHEREAS, Twin Leaf Partners LLC entered into a consulting agreement with Agios Pharmaceuticals, Inc. dated October 6, 2011 (hereinafter the "Consulting Agreement");

WHEREAS, Jeffrey D. Wilson was CEO of Twin Leaf Partners LLC on October 6, 2011;

WHEREAS, Jeffrey D. Wilson executed the Consulting Agreement on behalf of Twin Leaf Partners LLC; and

WHEREAS, Twin Leaf Partners LLC was voluntarily dissolved on or about January 4, 2022;

NOW THEREFORE, I, **Jeffrey D. Wilson of 6 Highwood Lane, Ipswich, Massachusetts 01938** (hereinafter the "Undersigned"), for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, do hereby irrevocably and unconditionally:

CONVEY, ASSIGN AND TRANSFER to Agios Pharmaceuticals, Inc., a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives (collectively hereinafter the "Assignee"), the Undersigned's entire right, title and interest throughout the world in the inventions and improvements disclosed in the applications set forth in the attached **EXHIBIT A**:

such application(s), and all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States and in all foreign countries and jurisdictions based in whole or in part on any of the said inventions and improvements (including any application for a utility model, design registration(s), and inventor's certificate(s));

the right to claim priority to the application(s) identified in the attached **EXHIBIT A** in relation to subject matter based in whole or in part on the identified application(s) and any of the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

the right to file in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor's certificate(s) for said inventions and improvements in the United States and all foreign countries under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and

the right to all causes of action, remedies, and other enforcement rights related to the identified application(s), including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the identified application(s) and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement.

The Undersigned authorizes and requests the U.S. and foreign patent issuing authority to issue any and all United States and foreign patents (including any application for a utility model, design registrations, and inventor's certificate(s)) on the said inventions and improvements to the Assignee.

The Undersigned covenants, that when requested and at the reasonable expense of the Assignee, in order to carry out in good faith the intent and purpose of this Assignment, the Undersigned shall (1) execute all provisional, non-provisional, divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other patent applications for the inventions and improvements which are subject of the said application(s), as the Assignee may reasonably request to effectuate fully this Assignment; (2) execute all rightful oaths, declarations, assignments, powers of attorney and other papers for the inventions and improvements which are subject of the said application(s); (3) communicate to the Assignee all facts known to the Undersigned relating to the inventions and improvements which are subject of the said application(s), and the history thereof; (4) cooperate with the Assignee in any interference, reexamination, reissue, opposition, dispute, post-grant proceeding or litigation involving any of the applications or patents for the inventions and improvements which are subject of the said application(s); and (5) take such further actions as the Assignee shall reasonably consider necessary or desirable for vesting title to the said inventions and improvements in the Assignee, or for securing, maintaining and enforcing proper patent protection for the said inventions and improvements.

The Undersigned covenants, that should the execution date, filing date and/or Application Number be not entered or be incorrect at the time the Undersigned executed this document, the Undersigned hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I, **Jeffrey D. Wilson**, have executed this document on the date indicated below.



Signature of Inventor

19 Aug 2022

Date


MA

Inventor's City, State of Residence

COMMONWEALTH OF MASSACHUSETTS:
COUNTY OF Essex:

On this 19th day of August, 2022, before me, the undersigned notary public,
personally appeared Jeffrey D Wilson, proved to me
through satisfactory evidence of identification, which were
FL Drivers License, to be the person whose name is signed on the
preceding or attached document in my presence.

SEAL



[Signature]
Notary Public
My Commission Expires 09/19/2025

ACCEPTED AND AGREED TO BY ASSIGNEE: **Agios Pharmaceuticals, Inc.:**

Signature: [Signature] Date: 9/6/2022
Printed name: Rona Nardone
Title: Senior Director, IP

EXHIBIT A

Application Number	Filing Date	Status	Patent Number	Issue Date	Title
62/589,822	Nov. 22, 2017	Expired			CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
62/691,709	June 29, 2018	Expired			CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
PCT/US2018/062197	Nov. 21, 2018	Inactive			CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
16/765,456	May 19, 2020	Granted	11,254,652	Feb. 22, 2022	CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE